Pharmaceutical Company Versartis Raises $25M in Series C
January 17, 2013
Versartis, a pharmaceuticals and biotech company focused on the treatment of metabolic diseases and endocrine disorders, has raised $25 million in Series C funding from lead investor Aisling Capital. Index Ventures, New Leaf Venture Partners and Advent Venture Partners also participated. The company’s lead product candidate is VRS-317, a once monthly form of human growth hormone that began its first clinical trial in October last year.